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Sirs: A considerable number of drugs can induce a
prolongation of cardiac repolarisation (QT interval)
and thereby predispose to the development of tor-
sades de pointes. A few reports [1–4] have discussed
a prolongation of the QT interval by methadone
used in the treatment of opiate addicts. In the pres-
ent report the case of a young heroine addict with a
collapse is described. The ECG showed QT interval
prolongation and torsades de pointes, probably due
to methadone therapy.
Case report
The subject of this case report is a 33-year-old fe-
male former heroin addict under controlled metha-
done therapy (120 mg/day). She also regularly con-
sumed alcohol and benzodiazepines. One week prior
to the cardiac events described below, she received
analgesics and inhalation therapy from her general
practitioner because of symptoms of bronchitis and
chest pain. Use of a salmeterol/fluticason inhaler re-
peatedly caused dizziness, and the patient stopped
using it. The analgesic was Etodolac (300 mg tab-
lets), an NSAID, which she took irregularly during
one week. On the admission day the patient called
the ambulance because she had had a very bad
night, felt exhausted, complained of chest pain, felt
dizzy, almost collapsed and experienced convulsions.
In the ambulance she lost consciousness and the
ECG recording showed ventricular tachycardia re-
quiring defibrillation (Fig. 1).
In the emergency room the patient was awake but
complained of chest pain. A 12 lead ECG showed si-
nus rhythm, with frequent ventricular extra beats
and a markedly prolonged QT interval (560 ms/
QTc 626 ms, Fig. 2).
In the intensive care unit several bouts of ventri-
cular tachycardia were recorded, some of which were
self-limiting while others required defibrillation.
Analysis of the rhythm disturbances showed not
only ventricular runs but also torsades de pointes
(Fig. 3). Laboratory measurements were normal with
the exception of elevated liver enzymes. Potassium
and magnesium levels were in the low normal range.
Methadone was stopped and replaced by morphine
i.v. which was then gradually reduced. Magnesium
and potassium were given i.v. to achieve high nor-
mal values, and -blockers to control the intermit-
tently rapid heart rate. Considering the fact that
with a slow pulse the QT interval becomes even
longer and also the vulnerable phase to develop
tachyarrhythmias, -blockers were used with the aim
of reducing the heart rate down to 100 beats per
minute.
Under this treatment cardiac rhythm disturbances
disappeared. Seven days after stopping methadone
the QT interval had returned to normal (440 ms,
Fig. 4).
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Fig. 1 Rhythm slip of ECG monitor in the ambulance showing ventricular tachycardia
Fig. 2 12 lead ECG at time of admission showing a QT interval of 560 ms (QTc 626 ms)
Fig. 3 Rhythm slip of monitor on ICU showing Torsade de pointes
Fig. 4 The 12 lead ECG after cessation of methadone showing a QT interval of 440 ms (QTc 440 ms)
The patient had been receiving methadone thera-
py for two years. Eighteen months previously she
had been hospitalised because of alcohol induced
acute pancreatitis. At this time she had been receiv-
ing 90 mg methadone/day and the QT interval was
already markedly prolonged (560 ms, QTc 650 ms).
Discussion
We strongly suspect that the torsades de pointes de-
scribed here were methadone induced. Prolonged
QT interval and torsades de pointes during metha-
done therapy have been described in some case re-
ports [1–3].
At the molecular level, 1--acetylmethadol (metha-
done) has been demonstrated to block cloned HERG
cardiac K+ channels [4]. This mechanism could lead
to a QT interval prolongation and ventricular arrhyth-
mias. Methadone is metabolized via CYP 3A4 as well
as Salmeterol and for example grapefruit juice or co-
cain which the patient assured not to have consumed.
It is first metabolized in the liver and then eliminated
through the kidneys. Simultaneous therapy with Dia-
zepam can slow down the metabolism. Our patient
had quite normal liver function despite her regular al-
cohol consumption and she never took Diazepam but
Lorazepam and Zolpidem [5]. Etodolac, which does
not cause QT prolongation and Salmeterol, for which
QT prolongation has only been described when used
in supra-therapeutic doses, are unlikely to have trig-
gered the patient’s rhythm disturbances, particularly
since she only used these drugs for a short time prior
to the cardiac event [6].
The normalisation of the long QT interval after
stopping methadone makes it most likely that the
torsades de pointes were caused by methadone, pos-
sibly facilitated by the borderline low potassium and
magnesium levels.
Since a considerable number of heroin/opiate ad-
dicts are treated with methadone, it is recommend
that these patients should have ECG controls to
check the QT interval.
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